Chemicals may induce cell proliferation directly as mitogens or indirectly via cell death with subsequent proliferation to replace lost cells. Chemically induced proliferation has been demonstrated to play a role in the carcinogenic process. A wide range of procedures and techniques are currently being used to define the quantitative relationship between the extent and duration of chemically induced cell proliferation and carcinogenic potential in different species and target organs. However, a limited database and nonstandard protocols and procedures for measuring cell proliferation have made it difficult to compare results between laboratories. Comparison of frequencies of S phase between control and treated animals is the most commonly used end point in cell proliferation studies and may be regarded as an indirect indication of a proliferative response.This response can be ascertained as labeling indexes (LI; percentage of cells in S phase) after the administration of the DNA precursor labels (tritiated thymidine; 3H-TdR; bromodeoxyuridine, BrdU) or through immunostaining of the endogenous cell replication marker, proliferating cell nuclear antigen (PCNA). Both approaches are applicable to tissue sections. An important issue in the design of experimental studies for measuring LI is determining how and when to investigate proliferative responses in relation to the chemical treatment regimen. Variables to consider when designing cell proliferation studies include the animal's age, chemical dose and method of treatment, choice and dose of label, time and length that the label is administered, and methods of quantitation. Study design considerations depend on the experimental objective. A common approach to characterize the complex relationship of cell proliferation and carcinogenic activity has been to focus on relatively early (less than 90 days) proliferative responses in the target tissue. However, a larger database on the duration and nature of the chemically induced proliferative response under bioassay conditions in the target cell population is required to more clearly establish the role of this end point in the cancer process. In addition, studies must also investigate mitogenic versus cytotoxic induction of cell proliferation in normal and preneoplastic cells and differential toxicity that may provide a preferential growth advantage to spontaneous or chemically induced intermediate or malignant cells.
Introduction
Carcinogenesis is a complex process in which normal cellular growth-control genes are altered by several, possibly sequential, mutational events with subse-quent clonal proliferation of the resulting precancerous or cancerous cells (1, 2) . Chemical carcinogens may act by inducing mutations and/or altering cellular growth control (3) . For nongenotoxic carcinogens, the induction of cell proliferation and its effects on the processes of tumor initiation, promotion, and progression appear to be important events in the formation of tumors (4) . Currently, there is a limited database for chemicals in which induced proliferation has been measured over time under bioassay conditions. The database assessing cell turnover in the developing neoplastic lesions is even more limited. A glossary of terms describing processes related to chemically induced cell proliferation is presented in Table 1 .
One class of chemical carcinogens is the genotoxicants. These compounds or their metabolites interact (7) . The potential for carcinogenic action related to cytotoxicants appears to be secondary to the induced cytolethality and subsequent cell proliferation. It has been suggested that, in the special case of those nongenotoxic chemicals that induce regenerative cell proliferation in the target organ secondary to cytotoxicity, the potential for carcinogenic activity may be decreased below exposures that do not induce a cytotoxic/proliferative response (6) .
Carcinogenic effects and activity may be different for mitogen-stimulated cell proliferation (5, 8, 9) . Mitogens tend to induce a relatively short burst of cell pro-liferation during chemically induced tissue growth immediately after exposure; this response is followed by a return of cell turnover rates in the normal tissue to baseline levels. Organ size, however, may remain elevated as long as the agent is administered, resulting in an increased number of proliferating cells in which to maintain the increased cell population. Although the mechanism of action of mitogenic carcinogens is unknown, these agents may provide a selective growth advantage to precancerous cells via growth inhibition of "normal" cells, inhibition of apoptosis in precancerous cells, and/or selective proliferative stimulation (10) (11) (12) (13) . Analysis of chemically induced cell proliferation in specific precancerous cell populations, i.e., hepatic foci, is needed to better understand the effect of mitogens on tumor development. Because mitogens may act via cellular receptors, the dose-response issue may be a consideration of the quantitative relationship between receptor occupancy and the triggering of the associated response. Experience with various specific receptor-mediated chemicals demonstrates that a range of exceedingly low doses to very high doses are required to elicit the same effective response. In the case of these agents, tissue-and species-specific responses must be related to carcinogenicity (14) .
Labeling Procedures
Multiple procedures can be used to assay chemically induced cell proliferation. The use of different protocols and procedures makes it difficult to define quantitatively the relationship between chemically induced cell proliferation and carcinogenic potential in different species and target organs. Variables of concern include animal age and species; chemical dose; treatment protocol; choice of label, timing, dose and duration of labeling; and methods of quantitation (15) .
Comparison of S-phase labeling indexes (LI) between control and treated animals is the most commonly used end point in cell proliferation studies. Because S phase is obligatory to cell replication, its frequency is regarded as an indicator of the cell proliferation response. Chemically induced cell proliferation is typically assessed after the administration of DNA precursor labels (3H-TdR or BrdU) or through the analysis of endogenous cell replication markers such as the proliferating cell nuclear antigen (PCNA; Fig. 1 (20) .
Recently, several monoclonal antibodies to endogenous cell-cycle-related nuclear proteins have been developed that can be used to preferentially identify proliferating cells (21) . PCNA, with peak concentrations seen in the nucleus in late G1/S phase, may prove to be one of the most versatile marker proteins because it obviates administration of the label and may be used to detect proliferating cells in both fixed embedded tissues, and in frozen tissue samples (22) . Immunohistochemical methods for detecting PCNA in archival study materials also have been reported (23) , suggesting use in retrospective cell proliferation analysis of previously studied material. PCNA analysis also has potential to identify the specific cell populations (G1, S, G2, M) that exist in the cell cycle and the pool of active proliferating cells; however, more characterization studies will be required for this purpose (22 
Labeling Study Designs
An important issue in the design of experimental studies for measuring LI is determining how and when to investigate the induced proliferative response in relation to the chemical treatment regimen (15) . The DNA-precursor label for detecting cells in S phase may be administered either by a single pulse injection or continuously for several days via an implanted osmotic pump. The pulse-labeling method gives an indication of the proliferation at a particular point in time. Continuous labeling detects all cells that were in S phase during the period that the pump is in place. The decision to use the pulse or pump label administration in a cell replication study depends on the experimental objective and the turnover rate of the target cell population. For example, it would be inappropriate to use a 6-day pump to assess increased chemically induced cell proliferation in the crypts of the small intestine because all cells would be labeled in the control group (Goldsworthy, unpublished observation) . A critical issue in using pulse-label techniques to measure LI is knowing when to sacrifice animals in relation to chemical treatment. A study design using multiple sacrifice times with prior pulse dosing is required to identify a relatively short time course in the induction of cell proliferation and is the method of choice when determining the time course and shape of the cell proliferation curve immediately after partial hepatectomy or chemical exposure. For evaluating the magnitude of replication in a target cell population with a relatively slow turnover rate (i.e., liver, kidney), to minimize diurnal variations, and to provide a greater window of time to detect a proliferative response, the pump-labeling procedure appears to be the method of choice (15, 25) .
In addition to issues of label administration and methodology, there are a number of other critical variables that must be addressed in the design of studies investigating cell proliferation. These factors include treatment regimen, route and dose of chemical exposure, species, strain, sex, age, diurnal variation, diet, environment, target cell population, method of quantitation, and statistical approaches. All of these factors may directly or indirectly impact on cell proliferation data accumulation and interpretation. For this reason, it is necessary to duplicate bioassay conditions in studies that attempt to correlate chemically induced cell proliferation to carcinogenic activity. For example, when evaluating the hepatic proliferation response to the hepatocarcinogens dichlorobenzene (DCB) and furan, we chose the same doses, dosing regimen, animal species, and experimental conditions that produced tumors in the rodent cancer bioassay (26, 27) . The response seen with cytotoxicant agent furan (Fig.  2) and the mitogenic agent DCB (Fig. 3) Investigation of cell-specific proliferation effects through the carcinogenic process is needed to further establish the importance of this end point in chemical carcinogenesis. Quantitation of chemically induced cell proliferation effects is currently available for a limited number of agents. Standard protocols and methodologies for design and measurement of chemically induced cell proliferation are necessary to generate data that may be formulated into a cohesive database. This database will be required to relate the extent, duration, and nature of chemically induced cell proliferation to carcinogenic activity. Cell loss rates must also be studied in conjunction with cell proliferation to accurately determine growth rates of the target cell population. Risk models incorporating cell proliferation data require quantitation of chemicals' effects on the growth and loss of specified target populations as well as the kinetics of those responses. Most important for improved cancer risk assessment is the identification of the mechanism for the chemically induced proliferative responses. Retrospective analysis of cell proliferation and genetic changes in previous studies, coupled with increased mechanistic information from cancer bioassays will yield critical information on the role of chemically induced cell proliferation in the carcinogenic process. Future studies need to investigate mitogenic and cytotoxic induction of differential toxicity and/or growth stimulation mechanisms that may provide a preferential growth advantage to spontaneous or chemically induced precancerous or malignant cells. Cell proliferative responses must be studied in conjunction with oncogene and growth factor expression and mutations, tissue injury and adaption, enzyme induction, and other parameters to ultimately understand complex relationships between cell proliferation and carcinogenesis. Information on the role of chemically induced cell proliferation throughout the cancer process will be valuable in investigations of mechanisms of carcinogenesis, development of assays for nongenotoxic carcinogenic activity, and selection of appropriate risk models.
